15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders

A compound according to formula (I):

• wherein:
• R1 is (CH2)nCO2R, (CH2)nCONR2R3, (CH2)nCH2OR4, (CH2)nCH2NR5R6, (CH2)nCH2N3, (CH2)nCH2Hal, (CH2)nCH2NO2, (CH2)nCH2SR20, (CH2)nCOSR21 or (CH2)n-2,3,4,5-tetrazol-1-yl, wherein:
• R is H or CO2R forms a pharmaceutically acceptable salt or a pharmaceutically acceptable ester;
• NR2R3 and NR5R6 are the same or different and comprise a free or functionally modified amino group;
• OR4 comprises a free or functionally modified hydroxy group;
• Hal is F, Cl, Br or I;
• SR20 comprises a free or functionally modified thiol group;
• R21 is H or COSR21 forms a pharmaceutically acceptable salt or a pharmaceutically acceptable thioester;
• n is 0 or 2;
• A, B, C and D is C1-C5 alkyl, alkenyl, or alkynyl or a C3-C5 allenyl group;
• Y is
• wherein
• R8 is CH3, and
• X is CH2, CH(CH3) or C(CH3)2;
• or
• Y is CH2, CH(CH3) or C(CH3)2, and
• X is
• wherein
• R8 is CH3, with the proviso that Y cannot be CH2 when X is
• and
• R7O comprises a free or functionally modified hydroxy group.